<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13239">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934568</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011X2X01B</org_study_id>
    <nct_id>NCT02934568</nct_id>
  </id_info>
  <brief_title>Ribociclib (LEE011) Rollover Study for Continued Access</brief_title>
  <official_title>An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to allow continued use of ribociclib (LEE011) as single agent or in
      combination with other investigational treatments in patients benefitting from treatment in
      an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary
      objective(s) or has been halted for other reasons.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Anticipated">April 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 27, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients enrolled and received LEE011</measure>
    <time_frame>up to 5 years (study duration)</time_frame>
    <description>Continued access to study treatment as a single agent or in combination with other investigational treatments until patients discontinue study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of time receiving study treatment</measure>
    <time_frame>up to 5 years (study duration)</time_frame>
    <description>Assessed by duration in days from start of study treatment until study treatment discontinuation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and nature of adverse events (AEs), serious adverse events (SAEs), non-fatal SAEs and liver function assays.</measure>
    <time_frame>up to 5 years (study duration)</time_frame>
    <description>The data include only AEs that started or worsened during the on-treatment-period, the treatment-emergent AEs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Continued Access to Study Treatment(s)</condition>
  <condition>Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>LEE011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in all combinations with LEE011 will be entered in one arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>Single agent LEE011 or in combination with other treatments</description>
    <arm_group_label>LEE011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is currently enrolled in an eligible Novartis-sponsored study and receiving
             ribociclib (LEE011) as single agent or in combination with other investigational
             treatment.

          2. Patient is currently deriving clinical benefit from the study treatment, as
             determined by the investigator.

        Exclusion Criteria:

          1. Patient has been permanently discontinued from ribociclib (LEE011) in the parent
             protocol for any reason.

          2. Patients who do not meet parent protocol criteria to continue study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Regents of the University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5930</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Granche</last_name>
      <phone>734-615-6638</phone>
      <email>granche@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Rashmi Chugh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Lyons</last_name>
      <email>Kate.Lyons@StJude.org</email>
    </contact>
    <investigator>
      <last_name>Giles Robinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>October 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ribociclib</keyword>
  <keyword>LEE011</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
